CDXI: AI 评分 51/100 — AI 分析 (4月 2026)

Cardax, Inc. is a biopharmaceutical company focused on developing and commercializing dietary supplements and pharmaceuticals targeting inflammation and oxidative stress. Their lead products include ZanthoSyn, an astaxanthin-based supplement, and pharmaceutical candidates CDX-101 and CDX-301.

Key Facts: AI Score: 51/100 Sector: Healthcare

公司概况

概要：

Cardax, Inc. is a biopharmaceutical company developing and commercializing dietary supplements and pharmaceuticals targeting inflammatory health. Its primary product, ZanthoSyn, an astaxanthin supplement, is sold through e-commerce and wholesale channels. The company's pharmaceutical pipeline includes CDX-101 for cardiovascular inflammation and CDX-301 for macular degeneration, positioning it within the competitive biotechnology landscape.

CDXI是做什么的？

Cardax, Inc., based in Honolulu, Hawaii, is a biopharmaceutical company dedicated to creating and marketing innovative dietary supplements and pharmaceuticals designed to combat chronic diseases driven by inflammation and oxidative stress. The company's flagship product, ZanthoSyn, is an inflammatory supplement formulated with astaxanthin, known for its enhanced absorption and purity. ZanthoSyn is currently available through e-commerce platforms and wholesale distribution channels. Founded with the vision of harnessing the therapeutic potential of natural compounds, Cardax is also actively developing a pipeline of pharmaceutical candidates. CDX-101, one of the company's leading pharmaceutical assets, is an astaxanthin-based formulation targeting cardiovascular inflammation and dyslipidemia, with a specific focus on severe hypertriglyceridemia. The company is also advancing CDX-301, a zeaxanthin-based pharmaceutical candidate intended for the treatment of macular degeneration. These pharmaceutical programs represent Cardax's strategic expansion into addressing significant unmet medical needs with innovative, science-backed solutions. Cardax's business model encompasses both the direct-to-consumer sale of dietary supplements and the development of prescription pharmaceuticals, allowing the company to generate revenue while simultaneously pursuing long-term growth opportunities in the pharmaceutical market. With a small team of 10 employees, Cardax is focused on efficiently advancing its product pipeline and expanding its market reach.

CDXI的投资论点是什么？

Cardax, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on inflammation and oxidative stress, coupled with its astaxanthin-based product line, aligns with growing consumer and medical interest in natural compounds for health and disease management. Key value drivers include the successful commercialization of ZanthoSyn, which currently has a gross margin of 63.6%, and the advancement of CDX-101 and CDX-301 through clinical trials. Growth catalysts include potential partnerships for pharmaceutical development and regulatory approvals for its drug candidates. However, the company's negative profit margin of -938.0% and reliance on e-commerce and wholesale channels for ZanthoSyn sales pose significant risks. The company's small market capitalization of $0.00B and high beta of -13.76 indicate substantial volatility. Successful navigation of regulatory hurdles and securing additional funding will be critical for Cardax to realize its potential.

CDXI在哪个行业运营？

Cardax, Inc. operates within the biotechnology and dietary supplement industries, both characterized by rapid innovation and evolving consumer preferences. The global biotechnology market is projected to reach trillions of dollars by 2026, driven by advancements in drug discovery and personalized medicine. The dietary supplement market is also experiencing steady growth, fueled by increasing consumer awareness of preventative healthcare. Cardax competes with both established pharmaceutical companies and smaller biotech firms in the development of novel therapeutics. The company's success depends on its ability to differentiate its products, navigate regulatory pathways, and secure strategic partnerships.

Biotechnology

Healthcare

CDXI有哪些增长机遇？

Expansion of ZanthoSyn Distribution: Cardax can expand its distribution channels for ZanthoSyn beyond e-commerce and wholesale to include retail pharmacies and healthcare providers. This broader reach could significantly increase sales volume and brand awareness. The global dietary supplements market is expected to grow, presenting a substantial opportunity for ZanthoSyn to capture a larger market share. Timeline: Ongoing.
Advancement of CDX-101 Clinical Trials: Successful completion of clinical trials for CDX-101 would represent a major milestone for Cardax, potentially leading to regulatory approval and commercialization. The market for cardiovascular drugs is substantial, and a novel treatment for severe hypertriglyceridemia could generate significant revenue. The timeline for clinical trials and regulatory approval is estimated to be several years. Market size: Multi-billion dollar market.
Development of CDX-301 for Macular Degeneration: The development of CDX-301 offers Cardax an opportunity to address the growing market for macular degeneration treatments. As the global population ages, the prevalence of macular degeneration is expected to increase, driving demand for effective therapies. Successful clinical trials and regulatory approval could position CDX-301 as a valuable asset. Timeline: Several years for clinical trials and approval. Market size: Billions of dollars.
Strategic Partnerships with Pharmaceutical Companies: Cardax can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its pharmaceutical candidates. These partnerships could provide access to funding, expertise, and distribution networks. The pharmaceutical industry is actively seeking innovative therapies, making strategic partnerships a viable growth strategy. Timeline: Ongoing.
Expansion into New Therapeutic Areas: Cardax can leverage its expertise in inflammation and oxidative stress to develop new products and therapies for other chronic diseases. This diversification could reduce the company's reliance on its existing product pipeline and create new revenue streams. The market for chronic disease treatments is vast, offering numerous opportunities for Cardax to expand its focus. Timeline: Long-term.

Gross Margin of 63.6% on ZanthoSyn sales indicates strong pricing power and efficient production.
Development of CDX-101 targets severe hypertriglyceridemia, a significant unmet medical need in cardiovascular health.
CDX-301 is being developed for macular degeneration, addressing a growing market driven by an aging population.
ZanthoSyn is sold through e-commerce and wholesale channels, providing diversified revenue streams.
The company has a small team of 10 employees, suggesting a lean operational structure.

CDXI提供哪些产品和服务？

Develops dietary supplements for inflammatory health.
Commercializes dietary supplements through e-commerce and wholesale channels.
Develops pharmaceutical candidates for chronic diseases.
Focuses on inflammation and oxidative stress.
Utilizes astaxanthin and zeaxanthin in its products.
Targets cardiovascular inflammation and macular degeneration.

CDXI如何赚钱？

Develops and patents proprietary formulations.
Sells ZanthoSyn directly to consumers through e-commerce.
Distributes ZanthoSyn through wholesale channels.
Seeks partnerships for pharmaceutical development.

Consumers seeking inflammatory health supplements.
Wholesale distributors of dietary supplements.
Potential pharmaceutical partners.
Patients with cardiovascular inflammation and dyslipidemia.
Patients with macular degeneration.

Proprietary formulations of astaxanthin and zeaxanthin.
Focus on enhanced absorption and purity of ingredients.
Development of pharmaceutical candidates targeting specific diseases.
Established e-commerce and wholesale distribution channels for ZanthoSyn.

什么因素可能推动CDXI股价上涨？

Upcoming: Results from clinical trials for CDX-101.
Upcoming: Results from clinical trials for CDX-301.
Ongoing: Expansion of ZanthoSyn distribution channels.
Ongoing: Potential partnerships with pharmaceutical companies.
Ongoing: New product development in inflammatory health.

CDXI的主要风险是什么？

Potential: Failure to obtain regulatory approvals for CDX-101 and CDX-301.
Potential: Competition from established pharmaceutical companies.
Ongoing: Limited financial resources.
Ongoing: Dependence on a small number of products.
Potential: Adverse events associated with its products.

CDXI的核心优势是什么？

Proprietary astaxanthin formulation (ZanthoSyn).
Focus on inflammation and oxidative stress.
Development pipeline of pharmaceutical candidates.
Existing e-commerce and wholesale distribution channels.

CDXI的劣势是什么？

Small market capitalization.
Negative profit margin.
Limited financial resources.
Reliance on a small number of products.

CDXI有哪些机遇？

Expansion of ZanthoSyn distribution.
Successful clinical trials for CDX-101 and CDX-301.
Strategic partnerships with pharmaceutical companies.
Expansion into new therapeutic areas.

CDXI面临哪些威胁？

Competition from established pharmaceutical companies.
Regulatory hurdles for pharmaceutical approvals.
Changes in consumer preferences for dietary supplements.
Potential adverse events associated with its products.

CDXI的竞争对手是谁？

Eloxx Pharmaceuticals, Inc. — Focuses on developing RNA-modulating therapeutics. — (ELOX)
Longboard Pharmaceuticals, Inc. — Develops novel medicines for neurological diseases. — (LGBI)
MedAvail Holdings, Inc. — Operates pharmacy solutions and technology. — (MDVLQ)
MicroCloud Hologram Inc. — Focuses on holographic technology. — (MICRD)
Model Performance Acquisition Corp. — A special purpose acquisition company (SPAC). — (MODC)

Key Metrics

MoonshotScore: 51/100

Company Profile

CEO: David G. Watumull
Headquarters: Honolulu, US
Employees: 10
Founded: 2013

AI Insight

AI analysis pending for CDXI

OTC Tier: OTC Other
Disclosure Status: Unknown

常见问题

What does Cardax, Inc. do?

Cardax, Inc. is a biopharmaceutical company that develops and commercializes dietary supplements and pharmaceutical candidates focused on inflammatory health and chronic diseases driven by inflammation and oxidative stress. Their primary product, ZanthoSyn, is an astaxanthin-based supplement sold through e-commerce and wholesale channels. The company is also developing CDX-101 for cardiovascular inflammation and CDX-301 for macular degeneration, aiming to address significant unmet medical needs with innovative, science-backed solutions in the healthcare sector.

What do analysts say about CDXI stock?

AI analysis is currently pending for CDXI, so there is no available analyst consensus. Key valuation metrics include a market cap of $0.00B, a P/E ratio of -0.00, and a profit margin of -938.0%. Growth considerations center on the successful commercialization of ZanthoSyn, the advancement of CDX-101 and CDX-301 through clinical trials, and potential partnerships with pharmaceutical companies. Investors should conduct their own thorough research before making any investment decisions.

What are the main risks for CDXI?

The main risks for Cardax, Inc. include its small market capitalization, negative profit margin, and limited financial resources. The company faces competition from established pharmaceutical companies and regulatory hurdles for pharmaceutical approvals. Additionally, there are risks associated with changes in consumer preferences for dietary supplements and potential adverse events associated with its products. Investing in CDXI involves significant risks due to its OTC listing and limited financial disclosure.